Israel Englander Actinium Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 117,454 shares of ATNM stock, worth $137,421. This represents 0.0% of its overall portfolio holdings.

Number of Shares

117,454

Previous 160,123 26.65%

Holding current value

$137,421

Previous $301,000 51.16%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$1.12 - $1.93 $47,789 - $82,351	-42,669 Reduced 26.65%	117,454 $147,000
Q3 2024 Nov 14, 2024	BUY	$1.72 - $8.0 $239,226 - $1.11 Million	139,085 Added 661.11%	160,123 $301,000
Q2 2024 Aug 14, 2024	SELL	$6.56 - $9.89 $304,206 - $458,628	-46,373 Reduced 68.79%	21,038 $155,000
Q1 2024 May 15, 2024	BUY	$5.0 - $9.2 $337,055 - $620,181	67,411 New	67,411 $527,000
Q1 2023 May 15, 2023	BUY	$8.51 - $14.26 $1.51 Million - $2.53 Million	177,392 Added 329.85%	231,172 $2.19 Million
Q4 2022 Feb 14, 2023	BUY	$7.05 - $14.41 $32,655 - $66,747	4,632 Added 9.42%	53,780 $573,000
Q3 2022 Nov 14, 2022	BUY	$4.81 - $8.48 $76,998 - $135,747	16,008 Added 48.3%	49,148 $363,000
Q2 2022 Aug 15, 2022	BUY	$4.71 - $7.11 $156,089 - $235,625	33,140 New	33,140 $159,000
Q1 2021 May 17, 2021	SELL	$7.62 - $9.79 $419,252 - $538,645	-55,020 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$7.8 - $12.64 $429,156 - $695,452	55,020 New	55,020 $429,000

Others Institutions Holding ATNM

# of Institutions

Shares Held

7.94M

Call Options Held

59.6K

Put Options Held

4.8K

View Full List

About Actinium Pharmaceuticals, Inc.

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $29.5M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

More about ATNM

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account